ARIAD Pharmaceuticals $ARIA announced that its Japanese partner Otsuka Pharmaceutical $OTSKF, received marketing approval in Japan for Iclusig. The drug is intended for patients with intractable chronic myeloid leukemia and relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.